Abstract
Red man syndrome is a rare but possibly serious adverse reaction during treatment with intravenous vancomycin. It is extremely important that pediatricians, especially in oncology, recognize this reaction and treat it appropriately. Following two case-reports from a pediatric oncology setting, a series of practical recommendations to prevent or handle red man syndrome are described.
This is a preview of subscription content, log in via an institution to check access.
References
Levy M, Koren G, Dupuis L, Read SE. Vancomycin-induced red man syndrome. Pediatrics. 1990;86(4):572–80.
Polk RE. Red man syndrome. Ann Pharmacother. 1998;32(7–8):840.
Sivagnanam S, Deleu D. Red man syndrome. Crit Care. 2003;7(2):119–20.
Doherty M. Algorithms for assessing the probability of an adverse drug reaction. Respiratory Medicine CME 2. 2009;63–7.
Korman TM, Turnidge JD, Grayson ML. Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. J Antimicrob Chemother. 1997;39(3):371–81.
Levy JH, Marty AT. Vancomycin and adverse drug reactions. Crit Care Med. 1993;21(8):1107–8.
UpToDate. Inc. Waltham, Massachussets, USA. 2011. http://www.utdol.com. Accessed on July 2011.
Vuagnat A, Stern R, Lotthe A, Schuhmacher H, Duong M, Hoffmeyer P, Bernard L. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29(4):351–7.
Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, et al. The study group. continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 2001;45(9):2460–7.
Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm. 1997;54:181–4.
Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2006. URL: http://cp.gsm.com. Updated February 2006.
Summary of Product Characteristics Vancocin. 2011. Available from http://www.fagg.be/. Accessed on 13 July 2011.
Polk RE, Healy DP, Schwartz LB, Rock DT, Garson ML, Roller K. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis. 1988;157(3):502–7.
Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and “red man syndrome”: comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother. 1990;34(4):550–4.
Renz CL, Thurn JD, Finn HA, Lynch JP, Moss J. Oral antihistamines reduce the side effects from rapid vancomycin infusion. Anesth Analg. 1998;87(3):681–5.
Sahai J, Healy DP, Shelton MJ, Miller JS, Ruberg SJ, Polk R. Comparison of vancomycin- and teicoplanin-induced histamine release and “red man syndrome”. Antimicrob Agents Chemother. 1990;34(5):765–9.
Wood MJ. Comparative safety of teicoplanin and vancomycin. J Chemother. 2000;12(S) 5:21–5.
Wazny LD, Daghigh B. Desensitization protocols for vancomycin hypersensitivity. Ann Pharmacother. 2001;35(11):1458–64.
Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334–6.
Funding
None
Conflicts of interest
There are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bauters, T., Claus, B., Schelstraete, P. et al. Vancomycin-induced red man syndrome in pediatric oncology: still an issue?. Int J Clin Pharm 34, 13–16 (2012). https://doi.org/10.1007/s11096-011-9593-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-011-9593-z